Placenta
Volume 29, Issue 9 , Pages 816-825 , September 2008

Human Equilibrative Nucleoside Transporters 1 and 2 may be Differentially Modulated by A2B Adenosine Receptors in Placenta Microvascular Endothelial Cells from Pre-eclampsia

,Accepted 27 June 2008.

References 

  1. Redman CW. Current topic: pre-eclampsia and the placenta. Placenta. 1991;12:301–308
  2. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of preeclampsia: linking placental. Microcirculation. 2002;9:147–160
  3. Baumwell S, Karumanchi SA. Pre-eclampsia: clinical manifestations and molecular mechanisms. Nephron Clin Pract. 2007;106:c72–c81
  4. Terán E, Escudero C, Vivero S, Enríquez A, Calle A. Hypertens Pregnancy. Intraplatelet cyclic guanosine-3′,5′-monophosphate levels during pregnancy and preeclampsia. 2004;23:303–308
  5. Villar J, Carroli G, Wojdyla D, Abalos E, Giordano D, Ba'aqeel H, et al. World Health Organization Antenatal Care Trial Research Group. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions?. Am J Obstet Gynecol. 2006;194:921–931
  6. Casanello P, Escudero C, Sobrevia L. Equilibrative nucleoside (ENTs) and cationic amino acid (CATs) transporters: implications in foetal endothelial dysfunction in human pregnancy diseases. Curr Vasc Pharmacol. 2007;5:69–84
  7. Di Paolo S, Volpe P, Grandaliano G, Stallone G, Schena A, Greco P, et al. Increased placental expression of tissue factor is associated with abnormal uterine and umbilical Doppler waveforms in severe preeclampsia with fetal growth restriction. J Nephrol. 2003;16:650–657
  8. Wareing M, Baker PN. Vasoconstriction of small arteries isolated from the human placental chorionic plate in normal and compromised pregnancy. Hypertens Pregnancy. 2004;23:237–246
  9. Egbor M, Ansari T, Morris N, Green CJ, Sibbons PD. Morphometric placental villous and vascular abnormalities in early- and late-onset pre-eclampsia with and without fetal growth restriction. Br J Gynaecol. 2006;113:580–589
  10. Marzioni D, Tamagnone L, Capparuccia L, Marchini C, Amici A, Todros T, et al. Restricted innervation of uterus and placenta during pregnancy: evidence for a role of the repelling signal Semaphorin 3A. Dev Dyn. 2004;231:839–848
  11. Carbillon L, Uzan M, Uzan S. Pregnancy, vascular tone, and maternal hemodynamics: a crucial adaptation. Obstet Gynecol Surv. 2000;55:574–581
  12. Vásquez G, Sanhueza F, Vásquez R, González M, San Martín R, Casanello P, et al. Role of adenosine transport in gestational diabetes-induced L-arginine transport and nitric oxide synthesis in human umbilical vein endothelium. J Physiol. 2004;560:111–122
  13. Yoneyama Y, Suzuki S, Sawa R, Yoneyama K, Power GG, Araki T. Increased plasma adenosine concentrations and the severity of preeclampsia. Obstet Gynecol. 2002;100:1266–1270
  14. Yoneyama Y, Sawa R, Suzuki S, Shin S, Power GG, Araki T. The relationship between uterine artery Doppler velocimetry and umbilical venous adenosine levels in pregnancies complicated by preeclampsia. Am J Obstet Gynecol. 1996;174:267–271
  15. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. Pflügers Arch. 2004;447:735–743
  16. Burnstock G. Purinergic signalling. Br J Pharmacol. 2006;147:S172–S181
  17. San Martín R, Sobrevia L. Gestational diabetes and the adenosine/L-arginine/nitric oxide (ALANO) pathway in human umbilical vein endothelium. Placenta. 2006;27:1–10
  18. Kurpis L, John D, Fox IH. Evidence for an adenosine receptor in human tissues. Adv Exp Med Biol. 1984;165:497–500
  19. Schocken DD, Schneider MN. Use of multiple radioligands to characterize adenosine receptors in human placenta. Placenta. 1986;7:339–348
  20. Read MA, Boura AL, Walters WA. Vascular actions of purines in the foetal circulation of the human placenta. Br J Pharmacol. 1993;110:454–460
  21. Puffinbarger NK, Hansen KR, Resta R, Laurent AB, Knudsen TB, Madara JL, et al. Production and characterization of multiple antigenic peptide antibodies to the adenosine A2b receptor. Mol Pharmacol. 1995;47:1126–1132
  22. Donoso MV, Lopez R, Miranda R, Briones R, Huidobro-Toro JP. A2B adenosine receptor mediates human chorionic vasoconstriction and signals through arachidonic acid cascade. Am J Physiol Heart Circ Physiol. 2005;288:H2439–H2449
  23. Jennings LL, Hao C, Cabrita MA, Vickers MF, Baldwin SA, Young JD, et al. Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENT1 and hENT2) in the central nervous system. Neuropharmacology. 2001;40:722–731
  24. Sawynok J, Reid AR, Liu XJ, Parkinson FE. Amitriptyline enhances extracellular tissue levels of adenosine in the rat hindpaw and inhibits adenosine uptake. Eur J Pharmacol. 2005;518:116–122
  25. Pinto-Duarte A, Coelho JE, Cunha RA, Ribeiro JA, Sebastião AM. Adenosine A2A receptors control the extracellular levels of adenosine through modulation of nucleoside transporters activity in the rat hippocampus. J Neurochem. 2005;93:595–604
  26. Lang I, Pabst MA, Hiden U, Blaschitz A, Dohr G, Hahn T, et al. Heterogeneity of microvascular endothelial cells isolated from human term placenta and macrovascular umbilical vein endothelial cells. Eur J Cell Biol. 2003;82:163–173
  27. Dye JF, Vause S, Johnston T, Clark P, Firth JA, D'Souza SW, et al. Characterization of cationic amino acid transporters and expression of endothelial nitric oxide synthase in human placental microvascular endothelial cells. FASEB J. 2004;18:125–127
  28. Casanello P, Torres A, Sanhueza F, González M, Farías M, Gallardo V, et al. Equilibrative nucleoside transporter 1 expression is downregulated by hypoxia in human umbilical vein endothelium. Circ Res. 2005;97:16–24
  29. Görlach A. Control of adenosine transport by hypoxia. Circ Res. 2005;97:1–3
  30. Radaelli T, Cetin I, Ayuk PT, Glazier JD, Pardi G, Sibley CP. Cationic amino acid transporter activity in the syncytiotrophoblast microvillous plasma membrane and oxygenation of the uteroplacental unit. Placenta. 2002;23:S69–S74
  31. Aguayo C, Casado J, Gonzalez M, Pearson JD, Martin RS, Casanello P, et al. Equilibrative nucleoside transporter 2 is expressed in human umbilical vein endothelium, but is not involved in the inhibition of adenosine transport induced by hyperglycaemia. Placenta. 2005;26:641–653
  32. Griffith DA, Jarvis SM. Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta. 1996;1286:153–181
  33. Devés R, Boyd CA. Transporters for cationic amino acids in animal cells: discovery, structure, and function. Physiol Rev. 1998;78:487–545
  34. Ongini E, Dionisotti S, Gessi S, Irenius E, Fredholm BB. Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1999;359:7–10
  35. Desai A, Victor-Vega C, Gadangi S, Montesinos MC, Chu CC, Cronstein BN. Adenosine A2A receptor stimulation increases angiogenesis by down-regulating production of the antiangiogenic matrix protein thrombospondin 1. Mol Pharmacol. 2005;67:1406–1413
  36. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53:527–552
  37. Wyatt AW, Steinert JR, Wheeler-Jones CP, Morgan AJ, Sugden D, Pearson JD, et al. Early activation of the p42/p44MAPK pathway mediates adenosine-induced nitric oxide production in human endothelial cells: a novel calcium-insensitive mechanism. FASEB J. 2002;16:1584–1594
  38. Farías M, San Martín R, Puebla C, Pearson JD, Casado JF, Pastor-Anglada M, et al. Nitric oxide reduces adenosine transporter ENT1gene (SLC29A1) promoter activity in human foetal endothelium from gestational diabetes. J Cell Physiol. 2006;208:451–460
  39. Puebla C, Farías M, González M, Vecchiola A, Aguayo C, Krause B, et al. High D-glucose reduces SLC29A1 promoter activity and adenosine transport involving specific protein 1 in human umbilical vein endothelium. J Cell Physiol. 2008;215:645–656
  40. Andresen BT, Gillespie DG, Mi Z, Dubey RK, Jackson EK. Role of adenosine A1 receptors in modulating extracellular adenosine levels. J Pharmacol Exp Ther. 1999;291:76–80
  41. Roberts JM, Gammill HS. Preeclampsia: recent insights. Hypertension. 2005;46:1243–1249
  42. Takeuchi T, Yoneyama Y, Suzuki S, Sawa R, Otsubo Y, Araki T. Regulation of platelet aggregation in vitro by plasma adenosine in preeclampsia. Gynecol Obstet Invest. 2001;51:36–39
  43. Escudero C, Sobrevia L. A hypothesis for preeclampsia: adenosine and inducible nitric oxide synthase in human placental microvascular endothelium. Placenta. 2008;29:469–483
  44. Bijlstra P, van Ginneken EE, Huls M, van Dijk R, Smits P, Rongen GA. Glyburide inhibits dipyridamole-induced forearm vasodilation but not adenosine-induced forearm vasodilation. Clin Pharmacol Ther. 2004;75:147–156
  45. Marshall JM. The roles of adenosine and related substances in exercise hyperaemia. J Physiol. 2007;583:835–845
  46. Hyde RJ, Cass CE, Young JD, Baldwin SA. The ENT family of eukaryote nucleoside and nucleobase transporters: recent advances in the investigation of structure/function relationships and the identification of novel isoforms. Mol Membr Biol. 2001;18:53–63
  47. Pastor-Anglada M, Casado FJ, Valdés R, Mata J, García-Manteiga J, Molina M. Complex regulation of nucleoside transporter expression in epithelial and immune system cells. Mol Membr Biol. 2001;18:81–85

PII: S0143-4004(08)00205-1

doi: 10.1016/j.placenta.2008.06.014

Placenta
Volume 29, Issue 9 , Pages 816-825 , September 2008

Article Tools

* Image Usage & Resolution